ÂÜÀòÂÒÂ×

Dr. Bernadette Ferraro serves as the Vice President, Immuno-oncology at NEUVOGEN and is responsible for leading a multidisciplinary team of scientists developing cutting edge immunoassays that support the company’s immuno-oncology clinical development programs. Prior to NEUVOGEN, she led the Preclinical Immuno-oncology team at Inovio Pharmaceuticals, where she oversaw the preclinical development of several cancer immunotherapies and played a key role in supporting research efforts enabling partnerships. Previously, she spent more than a decade developing prophylactic and therapeutic products for several different disease targets with a strong focus on immunotherapies designed to activate the adaptive immune response for the treatment of cancer. She also is a co-inventor on several patents directed to infectious disease and cancer immunotherapy products. Dr. Ferraro holds a BS degree in Microbiology from the University of South Florida, an MPH in Epidemiology, and a PhD in Molecular Medicine from the University of South Florida College of Medicine. She completed her post-doctoral training in the laboratory of David B. Weiner at the University of Pennsylvania Pearlman School of Medicine.